Siranomics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention Company Expects to Report Interim Clinical Data in the Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 18, 2021 /PRNewswire/  Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of a Phase 2 study of the company s lead drug candidate, STP705, for Keloid scar prevention. The Phase 2, multi-center, randomized, double-blind, multiple-arm, controlled study is designed to evaluate the safety and efficacy of various doses of STP705 in reducing post-keloidectomy keloid recurrence.

United statesMark corbaeStephanie carringtonMichael molyneauxPatrick luSiranomics incSirnaomics incChief medicalOrphan drug designationGlobal visionPatient centeredMedical officerஒன்றுபட்டது மாநிலங்களில்மாற்றாந்தாய் கேரிங்டன்மைக்கேல் மோலிநிபேட்ரிக் லு